Sugi Predict

Sugi Predict / Compounds / SCHEMBL56735

SCHEMBL56735

SCHEMBL56735

CC(C)CC(C)(NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 1/20 0.46
▸ CTSS P25774 4/20 0.43
▸ CTSK P43235 4/20 0.43
▸ CTSL P07711 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ AAK1 Q2M2I8 8/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CXCR2 P25025 1/20 0.38
▸ CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3821271 1.00 FPR2 (0.46) FPR2CTSSCTSKCTSLCTSB
SCHEMBL3823963 1.00 FPR2 (0.46) FPR2CTSSCTSKCTSLCTSB
SCHEMBL2258589 0.88 CA1 (0.40) FPR2CTSSCTSKCTSLCTSB
SCHEMBL7271757 0.88 CA1 (0.40) FPR2CTSSCTSKCTSLCTSB
SCHEMBL5422258 0.86 DGAT1 (0.42) CTSSCTSKCTSLCTSBAAK1
SCHEMBL5422252 0.86 DGAT1 (0.42) CTSSCTSKCTSLCTSBAAK1
SCHEMBL19209722 0.85 CTSK (0.42) FPR2CTSSCTSKCTSLCTSB
SCHEMBL1979479 0.83 CTSK (0.45) CTSSCTSKCTSLCTSBCA1
SCHEMBL2837383 0.83 CTSK (0.45) CTSSCTSKCTSLCTSBCA1
SCHEMBL1979477 0.83 CTSK (0.45) CTSSCTSKCTSLCTSBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360131-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 — — US disclosed
US-12065437-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-20 — — US disclosed
EP-3218372-B1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INT (DE) 2020-05-20 — — EP disclosed
US-10617675-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-04-14 — — US disclosed
EP-3292124-B1 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-22 — — EP disclosed
EP-3292124-B1 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-22 — — EP disclosed
US-10174044-B2 Fused pyridines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-01-08 — — US disclosed
US-10174044-B2 Fused pyridines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-01-08 — — US disclosed
CN-105683196-B Aryl ether based kinase inhibitors 百时美施贵宝公司 2018-12-21 — — CN disclosed
EP-3218371-B1 ARYL AND HETEROARYL-FUSED TETRAHYDRO-1,4-OXAZEPINE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INT (DE) 2018-09-26 — — EP disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 — — EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 — — US disclosed
EP-1968940-A1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS Novartis AG (CH) 2008-09-17 — — EP disclosed
US-20070249670-A1 Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof SMITHKLINE BEECHAM CORPORATION (US) 2007-10-25 — — US disclosed
EP-1812383-A1 GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF Smithkline Beecham Corporation (US) 2007-08-01 — — EP disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 — — WO disclosed
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 — — US disclosed
WO-2006052722-A1 GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2006-05-18 — — WO disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 — — US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249670-A1 Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof PYGM, PYGL, GYS1 FPR2 4719/4885CTSS 1634/4885CTSK 1424/4885
US-10174044-B2 Fused pyridines as kinase inhibitors AAK1, NCK1, ADCK1 FPR2 3955/4885CTSS 4146/4885CTSK 1791/4885
US-10617675-B2 Hepatitis C virus inhibitors HAVCR2, MAVS, EIF2AK2 FPR2 4520/4885CTSS 1740/4885CTSK 1909/4885
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 FPR2 3786/4885CTSS 301/4885CTSK 863/4885
US-12065437-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS FPR2 4217/4885CTSS 4005/4885CTSK 1350/4885
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 FPR2 176/4885CTSS 283/4885CTSK 781/4885
US-20240360131-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS FPR2 4217/4885CTSS 4005/4885CTSK 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.